Jeroen Van Dorp

6PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 17, 2026
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

|Jun 09, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

Chantal F Stockem, Alberto Gil-Jimenez, Hamza Ali

|Jul 24, 2024
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

Maksim A Chelushkin, Jeroen van Dorp, Sandra van Wilpe

|Jul 17, 2023
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Jeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann

|Feb 02, 2023
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Jeroen van Dorp, Christodoulos Pipinikas, Britt B M Suelmann

|Aug 05, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.

Anne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva

Pageof 1

Frequent Collaborators

6 joint publications

Michiel S Van Der Heijden

4 joint publications

Nick Van Dijk

3 joint publications

Lodewyk F A Wessels

2 joint publications

Maartje Alkemade